Přihlásit se Zaregistrujte se zdarma

Rok IPO společnosti Starpharma

Jaká je hodnota metriky Rok IPO společnosti Starpharma?

Hodnota metriky Rok IPO společnosti Starpharma Holdings Limited je 2000

Jaká je definice metriky Rok IPO?

IPO je rok počáteční veřejné nabídky akcií společnosti, kdy se akcie společnosti začnou veřejně obchodovat.

Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.

Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.

The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.

Rok IPO společností v sektoru Health Care sektor na ASX ve srovnání se společností Starpharma

Čemu se věnuje společnost Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Firmy s metrikou rok ipo podobnou společnosti Starpharma



  • Hodnota metriky Rok IPO společnosti Arq je 1999
  • Hodnota metriky Rok IPO společnosti TasFoods je 1999
  • Hodnota metriky Rok IPO společnosti hopTo je 1999
  • Hodnota metriky Rok IPO společnosti aap Implantate AG je 1999
  • Hodnota metriky Rok IPO společnosti Invigor je 1999
  • Hodnota metriky Rok IPO společnosti Encavis AG je 1999
  • Hodnota metriky Rok IPO společnosti Starpharma je 2000
  • Hodnota metriky Rok IPO společnosti SSR Mining Inc je 2001
  • Hodnota metriky Rok IPO společnosti Bread Inc je 2001
  • Hodnota metriky Rok IPO společnosti Exact Sciences je 2001
  • Hodnota metriky Rok IPO společnosti Cross Country Healthcares je 2001
  • Hodnota metriky Rok IPO společnosti Friedman Industries je 2001
  • Hodnota metriky Rok IPO společnosti Chevron je 2001